A disorder involving an excessive amount of body fat.
Comprehensive, easy-to-understand information about this condition
How we create this content →Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 5, 2026
European rare disease database
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning obesity disorder
Updated Feb 6, 2026
The biopharma industry is increasingly focused on the weight loss sector, projected to surpass $130 billion by 2035. Analysts anticipate significant developments in the oral market and novel mechanisms as 2026 approaches.
Novo Nordisk and Eli Lilly are competing in the rapidly growing obesity market, but the article argues that their approaches and products should not be directly compared. This highlights the diverse strategies within the sector as both companies seek to capture market share.
Eli Lilly executives view the successful launch of Novo Nordisk's Wegovy pill as a positive indicator for their own obesity treatment, orforglipron, anticipated to launch in Q2. This sentiment reflects confidence in the competitive landscape for weight management therapies.
Amgen is developing MariTide, an investigational obesity drug that aims to offer competitive weight loss results with extended dosing intervals of a month or longer. This approach could potentially shift the treatment paradigm for obesity management.
GSK shifts its strategy away from the competitive GLP-1 market to focus on downstream effects of obesity, particularly with its Phase III-ready FGF21 analog efimosfermin alfa targeting liver fibrosis. This decision highlights GSK's commitment to addressing obesity-related complications rather than weight loss alone.